Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

NCT01576029 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: CABAZITAXEL (XRP6258)
DRUG: DOCETAXEL (XRP6976)

Sponsor

Sanofi